| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Alison Wilson | Q92205647 |
| Paul Genever | Q38329035 | ||
| P2093 | author name string | Margeaux Hodgson-Garms | |
| Jessica E Frith | |||
| P2860 | cites work | Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells | Q26822005 |
| Matrix elasticity directs stem cell lineage specification | Q27860761 | ||
| Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement | Q27861120 | ||
| Dynamic stem cell heterogeneity | Q28080925 | ||
| Stochastic gene expression in a single cell | Q28131784 | ||
| In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment | Q28272235 | ||
| Biological activities encoded by the murine mesenchymal stem cell transcriptome provide a basis for their developmental potential and broad therapeutic efficacy | Q28507022 | ||
| Multilineage cells from human adipose tissue: implications for cell-based therapies | Q29547688 | ||
| Mesenchymal stem cells reside in virtually all post-natal organs and tissues | Q29617740 | ||
| Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo | Q29618057 | ||
| Bacterial persistence as a phenotypic switch | Q29618111 | ||
| Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue | Q29620725 | ||
| Mesenchymal progenitor cells in human umbilical cord blood | Q30168979 | ||
| A mesoderm-derived precursor for mesenchymal stem and endothelial cells | Q30498095 | ||
| Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. | Q33588019 | ||
| Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications. | Q33659105 | ||
| Repair of Torn Avascular Meniscal Cartilage Using Undifferentiated Autologous Mesenchymal Stem Cells: From In Vitro Optimization to a First-in-Human Study. | Q33722657 | ||
| Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow | Q33867848 | ||
| Cellular heterogeneity: do differences make a difference? | Q34052445 | ||
| Characterization and evaluation of mesenchymal stem cells derived from human embryonic stem cells and bone marrow | Q38985015 | ||
| Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study | Q39227266 | ||
| Lateral spacing of adhesion peptides influences human mesenchymal stem cell behaviour | Q39663872 | ||
| Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice | Q39736437 | ||
| Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential | Q39790403 | ||
| Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. | Q40235917 | ||
| Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study | Q40271549 | ||
| Multiparameter Analysis of Human Bone Marrow Stromal Cells Identifies Distinct Immunomodulatory and Differentiation-Competent Subtypes. | Q41763064 | ||
| Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients | Q42237533 | ||
| Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate | Q45863683 | ||
| Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion | Q45877573 | ||
| Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells | Q46286017 | ||
| Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy | Q46549703 | ||
| On the origin and impact of mesenchymal stem cell heterogeneity: new insights and emerging tools for single cell analysis. | Q47404854 | ||
| Adaptation to Stochastic Temporal Variations in Intratumoral Blood Flow: The Warburg Effect as a Bet Hedging Strategy | Q47843888 | ||
| A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy | Q47968884 | ||
| Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study | Q48321211 | ||
| Effect of the Microenvironment on Mesenchymal Stem Cell Paracrine Signaling: Opportunities to Engineer the Therapeutic Effect | Q48833850 | ||
| Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. | Q50790713 | ||
| Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. | Q51520774 | ||
| Phenotypic Plasticity, Bet-Hedging, and Androgen Independence in Prostate Cancer: Role of Non-Genetic Heterogeneity. | Q53078069 | ||
| Non-genetic heterogeneity--a mutation-independent driving force for the somatic evolution of tumours. | Q53311592 | ||
| Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. | Q55017527 | ||
| Bet hedging or not? A guide to proper classification of microbial survival strategies | Q57065008 | ||
| Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study | Q57254134 | ||
| Mesenchymal Stromal Cells: From Discovery to Manufacturing and Commercialization | Q58855503 | ||
| Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use | Q70803151 | ||
| Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers | Q77398364 | ||
| Isolation of multipotent mesenchymal stem cells from umbilical cord blood | Q79202796 | ||
| Population dynamics of mesenchymal stromal cells during culture expansion | Q82846450 | ||
| Modifiers of mesenchymal stem cell quantity and quality | Q88185522 | ||
| Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities | Q88957419 | ||
| Cellular Heterogeneity: Benefits Besides Bet-Hedging | Q89410374 | ||
| Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases | Q34367266 | ||
| Noise propagation in gene networks | Q34406341 | ||
| Phenotypic characterization, osteoblastic differentiation, and bone regeneration capacity of human embryonic stem cell-derived mesenchymal stem cells | Q34546544 | ||
| Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. | Q34600820 | ||
| Historical claims and current interpretations of replicative aging | Q34713128 | ||
| Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients | Q34753440 | ||
| Transcriptome-wide noise controls lineage choice in mammalian progenitor cells | Q34780848 | ||
| Human embryonic stem cell-derived mesoderm-like epithelium transitions to mesenchymal progenitor cells. | Q34938156 | ||
| Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial | Q34979725 | ||
| Decellularized extracellular matrices produced from immortal cell lines derived from different parts of the placenta support primary mesenchymal stem cell expansion | Q36268003 | ||
| A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential | Q36399846 | ||
| A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction | Q36634299 | ||
| Massive Clonal Selection and Transiently Contributing Clones During Expansion of Mesenchymal Stem Cell Cultures Revealed by Lentiviral RGB-Barcode Technology | Q36808567 | ||
| Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study | Q36861751 | ||
| Engineering bone tissue substitutes from human induced pluripotent stem cells | Q36884199 | ||
| Clinical-scale expansion of mesenchymal stromal cells: a large banking experience | Q36923358 | ||
| Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy | Q37000326 | ||
| Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial. | Q37042633 | ||
| Self-renewal and differentiation capacity of young and aged stem cells | Q37148596 | ||
| Bistability, epigenetics, and bet-hedging in bacteria | Q37184651 | ||
| Enumeration of the colony-forming units-fibroblast from mouse and human bone marrow in normal and pathological conditions | Q37367098 | ||
| A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction | Q37473636 | ||
| Stem cell states, fates, and the rules of attraction | Q37475461 | ||
| The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine | Q37720654 | ||
| The origins of mesenchymal stromal cell heterogeneity | Q37857736 | ||
| Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. | Q37881520 | ||
| Turning round: multipotent stromal cells, a three-dimensional revolution? | Q37893153 | ||
| Stem cell cultivation in bioreactors | Q37897334 | ||
| Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development | Q37968323 | ||
| Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. | Q37999098 | ||
| Functional heterogeneity of mesenchymal stem cells: implications for cell therapy | Q38003340 | ||
| Cell therapy with autologous mesenchymal stem cells-how the disease process impacts clinical considerations | Q38113315 | ||
| Donor variation in the growth properties and osteogenic potential of human marrow stromal cells | Q38319053 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P921 | main subject | cell differentiation | Q210861 |
| P304 | page(s) | 1112 | |
| P577 | publication date | 2019-05-16 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Multiplicity of Mesenchymal Stromal Cells: Finding the Right Route to Therapy | |
| P478 | volume | 10 |
| Q96303206 | Biological Considerations in Scaling Up Therapeutic Cell Manufacturing |
| Q101477936 | Bringing tendon biology to heel: Leveraging mechanisms of tendon development, healing, and regeneration to advance therapeutic strategies |
| Q91894529 | Comparison of Properties of Stem Cells Isolated from Adipose Tissue and Lipomas in Dogs |
| Q91964936 | Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases |
| Q91815545 | Polysaccharide-Based Systems for Targeted Stem Cell Differentiation and Bone Regeneration |
| Q94474186 | Single-cell transcriptional networks in differentiating preadipocytes suggest drivers associated with tissue heterogeneity |
| Q89769517 | Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery |
| Q90643200 | Use of Human Umbilical Cord and Its Byproducts in Tissue Regeneration |
| Q99712161 | Xeno-Free Spheroids of Human Gingiva-Derived Progenitor Cells for Bone Tissue Engineering |
Search more.